Topiramate in non-approved indications and acute myopia or angle closure glaucoma

British Journal of Clinical Pharmacology

Volumn 60, Issue 5, 2005, Pages 578-579

  Cereza, Gloria ^a   Pedrós, Consuelo ^a   Garcia, Núria ^b   Laporte, Joan Ramon ^c  

^a Fundacion Institut Catala de Farmacologia   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; TOPIRAMATE;

ACUTE DISEASE; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; EPILEPSY; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; MYOPIA; PREVALENCE; PRIORITY JOURNAL; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; ANXIETY DISORDERS; FEMALE; FRUCTOSE; GLAUCOMA, ANGLE-CLOSURE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; MYOPIA; PAIN; PERSONALITY DISORDERS; WEIGHT LOSS;

EID: 27444438492     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02470.x     Document Type: Letter

References (5)

1. Thambi L, Kapcala LP, Chambers W, Nourjah P, Beltz J, Chen M, Lu S. Topiramate-associated secondary angle-closure glaucoma: a case series. Arch Opthalmol 2002; 120: 1106.
2. Shorron SD. Epidemiology, classification, natural history, and genetics of epilepsy. Lancet 1990; 336: 93-6.
3. Anonymous. In the shadow of epilepsy. Lancet 1997; 349: 1851.
4. Lenzer J. Pfizer pleads guilty, but drug sales continue to soar. BMJ 2004; 328: 1217.
5. Anonymous. Topiramate approvable in migraine prevention. Scrip 2004; 2904: 24.